Ozempic Gastroparesis Settlement: Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Science to Targeted Risk Awareness

For decades, public health communication has centered on general wellness and the broad dissemination of scientific information. This legacy framework, built around accessible health literacy, has served as a foundation for understanding how lifestyle factors and medical interventions interact with human physiology. Within this tradition, discussions of pharmaceutical therapies have typically focused on their intended benefits and common side effects, framed within a context of overall health maintenance. As the landscape of chronic disease management evolves, a more specific area of concern has emerged: the relationship between medication exposure and gastrointestinal function. This pivot requires moving from general health principles to a focused examination of how certain drug therapies may influence digestive processes over time. The transition from broad health education to targeted risk awareness is particularly relevant when considering medications prescribed for metabolic conditions. The shift in focus now turns to the occupational and clinical implications of long-term drug exposure, specifically regarding medications like Ozempic. Understanding the criteria for potential settlements related to gastroparesis requires a careful examination of exposure patterns and their documented consequences. This represents a natural progression from general health science into the specialized domain of pharmaceutical risk assessment, where the legacy of public health communication meets the need for precise, actionable information about specific therapeutic outcomes.

Find Out If You Qualify for Compensation →

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). GLP-1 receptor agonists work by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. This pharmacologic effect on gastric motility is central to the mechanistic pathway linking Ozempic to gastroparesis. By delaying gastric emptying, Ozempic can exacerbate or induce symptoms consistent with gastroparesis, particularly in susceptible individuals.

Clinical Trial Evidence of Gastrointestinal Adverse Reactions

Clinical trial data demonstrate a clear association between Ozempic use and gastrointestinal adverse reactions. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which aligns with the known mechanism of delayed gastric emptying.

Adequacy of Warnings and Settlement Criteria

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. While the prescribing information lists gastrointestinal adverse reactions, it does not explicitly warn of gastroparesis as a distinct adverse event. The label notes that Ozempic has not been studied in patients with a history of pancreatitis and recommends considering other antidiabetic therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about the risk of gastroparesis or delayed gastric emptying beyond the general gastrointestinal effects. This gap in labeling may affect settlement-related considerations for affected patients, as it raises questions about whether the manufacturer provided adequate notice of the potential for severe gastric motility disorders. Settlement criteria for Ozempic-related gastroparesis typically involve demonstrating a causal link between Ozempic use and the development of gastroparesis. Key factors include the timeline between exposure and documented harm. Patients who developed gastroparesis symptoms during or shortly after Ozempic treatment, particularly during dose escalation when gastrointestinal effects are most common, may have stronger claims. The clinical trial data show that gastrointestinal adverse reactions occurred more frequently during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting a temporal relationship. Additionally, patients who discontinued Ozempic due to gastrointestinal adverse reactions and subsequently developed persistent gastroparesis symptoms may be eligible for settlement consideration. Settlement-related considerations also include the severity and duration of harm. Gastroparesis can lead to chronic symptoms, nutritional deficiencies, and reduced quality of life. Patients with documented gastroparesis via gastric emptying scintigraphy or other diagnostic methods, and who have no other identifiable cause for the condition, may have stronger claims. The absence of explicit warnings about gastroparesis in the prescribing information could be a factor in settlement negotiations, as it may indicate inadequate risk communication. In summary, the evidence demonstrates a mechanistic and clinical link between Ozempic and gastroparesis through delayed gastric emptying. Clinical trial data show a dose-dependent increase in gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The adequacy of warnings is questionable, as the label does not specifically mention gastroparesis. Settlement criteria likely focus on the timeline between exposure and harm, severity of symptoms, and the absence of alternative causes. Patients affected by Ozempic-related gastroparesis should consult with legal and medical professionals to evaluate their individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

What evidence links Ozempic to gastroparesis?

Clinical trial data demonstrate a clear association between Ozempic use and gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic (32.7% to 36.4%) compared to placebo (15.3%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The mechanism involves delayed gastric emptying, a known effect of GLP-1 receptor agonists.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.